BIO-RAD LABORATORIES, INC.

Capital Structure and Liquidity Bio-Rad maintains a strong liquidity position with $507.2 million in cash and equivalents and a current ratio of 3.21, indicating robust short-term financial health. The company's debt-to-equity ratio of 0.12 suggests a conservative capital structure, with long-term debt at $802.9 million and total equity at $6.85 billion. Free cash flow of $78.1 million in Q1 2026 supports operational flexibility and potential for shareholder returns. ### Profitability and Returns Despite a net loss of $527.1 million in Q1 2026, Bio-Rad's gross profit of $309.4 million reflects strong product margins. However, the company's return on equity of -7.69% and return on assets of -5.38% indicate significant underperformance relative to industry norms, driven by high operating expenses and non-operating losses. ### Segments and Geographic Exposure Bio-Rad operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment focuses on research and biopharmaceutical production, while the Clinical Diagnostics segment serves hospital and reference laboratories. Revenue concentration data is not provided, but the company's global presence in diagnostics and life sciences suggests exposure to both domestic and international markets. ### Growth Trajectory The company's revenue of $592.1 million in Q1 2026 shows a slight decline from the previous quarter's $10.58 billion in total assets. Outlook data is not provided, but the company's capital expenditure of $30 million and operating cash flow of $108.1 million suggest ongoing investment in growth and operational efficiency. ### Risk Factors Bio-Rad faces medium dilution risk, with key flags indicating potential for equity offerings or dilutive events. The company's liquidity risk is low, supported by strong cash reserves and a healthy current ratio. Regulatory and competitive risks are present, with healthcare reform measures and competition from larger firms with greater financial resources posing challenges. ### Recent Events Recent filings include updates on property and equipment, lease accounting under ASC 842, and the adoption of ASU 2025-01. The company also noted the impact of healthcare reform on pricing and demand for its products.